Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum (Q35824978)

10 August 2017

1 reference

title

Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum (English)

1 reference

10 August 2017

liver transplantation

1 reference

inferred from title

hepatocellular carcinoma

1 reference

inferred from title

author

Andrew Kenneth Burroughs

series ordinal

1

object named as

Andrew Burroughs

1 reference

10 August 2017

Daniel Hochhauser

2

1 reference

PubMed ID

15231247

10 August 2017

Tim Meyer

series ordinal

3

1 reference

10 August 2017

1 July 2004

1 reference

Lancet Oncology Commission

10 August 2017

1 reference

10 August 2017

5

1 reference

10 August 2017

409-418

1 reference

10 August 2017

7

1 reference

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

10 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Clinical trials in primary hepatocellular carcinoma: current status and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Systemic treatment of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Treatment of hepatocellular carcinoma with adriamycin.Preliminary communication

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Further experience in treating patients with hepatocellular carcinoma in Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

4'Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Mitozantrone as single agent therapy in hepatocellular carcinoma. A phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Mitoxantrone in Patients Affected by Hepatocellular Carcinoma with Unfavorable Prognostic Factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Chemotherapy studies in primary liver cancer. A prospective randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Primary liver cancer. An Eastern Cooperative Oncology Group Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Prognostic factors in patients affected by hepatocellular carcinoma treated with systemic chemotherapy: the experience of the National Cancer Institute of Milan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Apoptosis: a link between cancer genetics and chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Multidrug resistance in cancer: role of ATP-dependent transporters

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Mechanisms of resistance to cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Genetic changes and histopathological grades in human hepatocellular carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

A novel protein overexpressed in hepatoma accelerates export of NF-kappa B from the nucleus and inhibits p53-dependent apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Regulatory peptide receptors in human hepatocellular carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Low-dose thalidomide treatment for advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Analysis of tumor characteristics and survival in liver transplant recipients with incidentally diagnosed hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Is the pathologic TNM staging system for patients with hepatoma predictive of outcome?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Percutaneous ethanol injection in the treatment of hepatocellular carcinoma. A multicenter survey of evaluation practices and complication rates

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

MELD and PELD: application of survival models to liver allocation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Non-resective ablation and liver transplantation in patients with cirrhosis and hepatocellular carcinoma (HCC): safety and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Effect of preoperative radiological treatment of hepatocellular carcinoma before liver transplantation: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Living donor liver transplantation in adults: outcome in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Hepatocellular carcinoma: a prime indication for living donor liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Living-donor liver transplantation for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Living-donor versus cadaveric liver transplantation for non-resectable small hepatocellular carcinoma and compensated cirrhosis: a decision analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Prognostic prediction and treatment strategy in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Domino liver transplants for metabolic disorders: experience with familial amyloidotic polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Sequential liver transplantation: 27 cases in 25 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

El trasplante hepático dominó o secuencial, ¿es una técnica factible?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Evolution of liver transplantation for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901508-6

7 January 2021

10.1016/S1470-2045(04)01508-6

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15231247